SMJ- Sohag Medical Journal, Vol. 29 No(2) 2025

Print ISSN 1687-8353 Online ISSN 2682-4159

Review Article

Helicobacter pylori and its potential relationship to Ischemic Heart Disease

Mohammed Khalaf Mohammed

*Internal Medicine Department, Faculty of Medicine, Sohag University, Sohag, Egypt

ABSTRACT

Helicobacter pylori (H. pylori) is a common bacterium that causes a variety of gastrointestinal and duodenal illnesses. It was traditionally believed that H. pylori infection only affected the digestive system, but recent studies show that it can impact general health and contribute to the development of several non-gastric disorders, including ischemic heart disease (IHD).

Because IHD is an important cause of mortality and disability worldwide, it is essential to identify other risk factors for IHD beyond the traditional ones associated with cardiovascular disease.

This article provides a concise overview of the current literature regarding the potential association between H. pylori infection and IHD.

We investigate the hypothesized biological pathways that connect Helicobacter pylori to heart disease, which include systemic inflammatory response, molecular mimicry, platelet activation, and differences in lipid profiles.

We provide a critical review of the epidemiological studies that have looked into this link, drawing attention to the results that are both consistent with and inconsistent with one another. We go on to talk about the research gaps, clinical consequences, and future directions for understanding the intricate interplay between H. pylori and IHD. In order to encourage more study in this dynamic area, this review provides a thorough and fair assessment of the current data.

Keywords : Ischemic Heart Disease, Inflammation, Helicobacter pylori Infection, Epidemiology, Risk Factors

DOI : 10.21608/SMJ.2025.383554.1569 **Received:** May 09 , 2025 **Accepted:** June 08 , 2025

Published: July 01, 2025

Corresponding Author: Mohammed Khalaf Mohammed **E.mail**: mohamed.khalaf@med.sohag.edu.eg

Citation: Mohammed Khalaf Mohammed., Helicobacter pylori and its potential relationship to Ischemic Heart Disease **SMJ,**2025 Vol. 29 No (2) 2025 171- 177

Introduction

1. A Brief Overview

Bacteria known as Helicobacter pylori are spiral-shaped and Gram-negative. They infect the gastric mucosa of about 50% of the global population. (1)

Despite its mostly known association with gastroduodenal disorders like gastric cancer, peptic ulcer disease, and chronic gastritis, (2)

Multiple extra-gastric symptoms are being linked to H. pylori infection. (3)

Although not as well-established as the gastrointestinal links, these extra-gastric associations have expanded the range of human health issues caused by H. pylori.

The most prevalent cause of diminished blood supply to the heart muscle in ischemic heart disease (IHD), also called coronary artery disease, is atherosclerosis, which is the accumulation of plaque in the coronary arteries.

Internal heart disease encompasses a variety of clinical symptoms, including myocardial infarction, unstable angina, unstable angina, and sudden cardiac death. (4)

Globally, IHD continues to rank as the top cause of mortality and disability, even though there have been advancements in prevention and treatment. (5)

The conventional wisdom is that a person's blood pressure, cholesterol levels, diabetes, smoking, and family history all increase the likelihood of coronary heart disease. (6)

There may be other, less well-known etiological agents at work in IHD because a large percentage of cases occur in people who do not have these traditional risk factors.

More and more research in the last few decades has pointed to chronic infections as a possible contributor to the development of atherosclerosis and IHD. (7) It has recently come to light that Helicobacter pylori is one infectious agent that may increase the risk of cardiovascular disease. While there are some discrepancies and debates, the increasing amount of epidemiological evidence lends credence to this idea, which is based on various hypothesized biological pathways. With an eye toward providing a thorough and up-to-date analysis of the evidence connecting H. pylori infection to IHD, this review delves into the suggested mechanisms, epidemiological results, clinical consequences, and areas that require more investigation.

2. Helicobacter pylori:

H. pylori is a meticulously designed bacteria that has evolved to thrive in the extremely acidic conditions found in the human stomach. (8)

Untreated infections, which generally manifest in childhood via fecal-oral or oral-oral pathways, can last a lifetime. By employing flagella for movement and urease to neutralize stomach acid, the bacteria establishes a micro-neutral environment as it colonizes the gastric mucosa, typically in the antrum. (9)

Even in those without symptoms, the stomach mucosa experiences a persistent inflammatory response when infected with Helicobacter pylori. The hallmark of H. pylori-associated gastritis is this inflammation, which is marked by the infiltration of neutrophils, lymphocytes, and macrophages. (10)

Severe gastroduodenal illnesses can develop in vulnerable persons who have chronic gastritis. In addition, the International Agency for Research on Cancer (IARC) has categorized H. pylori as a Group 1 carcinogen because of its high link with stomach adenocarcinoma and gastric mucosa-associated lymphoid tissue (MALT) lymphoma. (11)

There are invasive and non-invasive ways to diagnose H. pylori infection. A quick urine test, histology, culture, or upper endoscopy with biopsy are all examples of invasive procedures. There are non-invasive procedures that can be used to detect H. pylori, such as the urea breath test (UBT), stool antigen test (SAT), and serology. (12) While serology is convenient and widely used in epidemiological studies, it indicates past or present infection and does not differentiate between active and eradicated infection, which is a limitation when assessing current disease risk.

3. Ischemic Heart Disease: Etiology and Pathogenesis

IHD is predominantly caused by atherosclerosis, a chronic inflammatory process that leads to the formation of atherosclerotic plaques within the arterial walls. (13)

The artery lumen can be gradually narrowed by these plaques, which consist of inflammatory cells, fibrous tissue, and lipids, and this can reduce blood flow to the heart. Myocardial infarction and unstable angina can occur as a result of acute

thrombotic events caused by plaque erosion or rupture. [14]

The pathogenesis of atherosclerosis is complex and multifactorial, involving endothelial dysfunction, lipid accumulation, inflammation, and smooth muscle cell proliferation. [15]
Traditional risk factors including high cholesterol, high blood pressure, smoking, diabetes, and family history worsen endothelial damage, which starts the atherosclerotic process. [6]
Atherosclerosis, from its inception to its evolution and plaque rupture, is now understood to be largely influenced by chronic inflammation. [16]
Chronic infections, autoimmune illnesses, and psychological stress are emerging as additional risk factors for IHD, in addition to the classic ones. [17]
Plaque formation, endothelial dysfunction, and systemic inflammation are all put forward by the "infection hypothesis" of atherosclerosis. [7]
There is mixed evidence linking atherosclerosis to certain pathogens, however studies have looked at Chlamydia pneumoniae, CMV, and Porphyromonas gingivalis. [18]
Because of its large global frequency and ability to create chronic systemic inflammation, Helicobacter pylori has also been considered within this setting.

4. Proposed Mechanisms Linking H. pylori to Ischemic Heart Disease

Lots of theories have been put out to try to explain how chronic H. pylori infection could worsen or cause IHD. A combination of more than one of these mechanisms can raise the risk of cardiovascular disease:

4.1 Systemic Inflammation:

A systemic inflammatory response, characterized by elevated levels of pro-inflammatory cytokines such C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α), is known to occur in chronic H. pylori infection. [19]
These inflammatory mediators don't stay in the stomach; they travel throughout the body, where they may affect the endothelium of blood vessels and add to the development of atherosclerosis. [20]
Endothelial dysfunction, lipid oxidation, and plaque instability are all greatly exacerbated by chronic low-grade inflammation, which is a major step in atherogenesis. [16]
Thus, systemic inflammation caused by H. pylori could hasten atherosclerosis and raise the risk of IHD.

4.2 Molecular Mimicry:

One example of molecular mimicry is the development of cross-reactive immune responses when microbial antigens resemble antigens found in host tissues. [21]
It has been hypothesized that antibodies generated against certain H. pylori antigens may cross-react with cardiac or vascular proteins, leading to autoimmune-mediated damage of the endothelium or myocardium. Specific H. pylori virulence factors, such as cytotoxin-associated gene A (CagA), have been suggested as potential candidates for molecular mimicry in the context of cardiovascular disease, although direct evidence remains limited and requires further investigation. [22]

4.3 Platelet Activation and Hypercoagulability:

Helicobacter pylori infection may influence platelet function and the coagulation cascade, potentially promoting a prothrombotic state. Studies have shown that H. pylori can directly activate platelets and enhance platelet aggregation in vitro. [23]
Furthermore, some studies have reported increased levels of procoagulant factors and markers of hypercoagulability in individuals with H. pylori infection. [24]
Enhanced platelet reactivity and hypercoagulability could increase the risk of thrombus formation in coronary arteries, contributing to acute coronary events in the setting of pre-existing atherosclerosis.

4.4 Lipid Profile Alterations:

One of the most important conventional risk factors for IHD is dyslipidemia. The effect of Helicobacter pylori infection on lipid profiles has been the subject of some research. Multiple studies have shown different relationships between H. pylori infection and various lipid profiles, including increased total cholesterol, LDL-cholesterol, and triglycerides, or decreased HDL-cholesterol, [25] and no significant association. [26]
If H. pylori does indeed influence lipid metabolism unfavorably, it could indirectly contribute to IHD risk by exacerbating dyslipidemia and accelerating atherosclerosis. However, the consistency and clinical significance of H. pylori-related lipid profile alterations require further clarification.

4.5 Endothelial Dysfunction:

Atherosclerosis begins with endothelial dysfunction, which is defined as raised endothelial permeability and decreased endothelial nitric oxide (NO) production. [27]

Endothelial dysfunction may be a consequence of H. pylori infection, either indirectly through systemic inflammation or directly through the effects of bacterial proteins. It has been demonstrated in vitro that components of H. pylori can hinder endothelial function. [28] There is evidence that persistent inflammation can cause endothelial dysfunction. Atherosclerosis could be accelerated and worsened by H. pylori because it undermines endothelial function and integrity.

5. Epidemiological Evidence: Examining the Association

Many epidemiological studies have looked at the link between H. pylori infection and IHD, but their methods, subjects, and results have varied. There is some inconsistency in the results of this research, and the overall strength of the evidence is still up for question.

5.1 Cross-Sectional Studies:

A number of cross-sectional investigations have shown that H. pylori infection is associated with cardiovascular risk factors or the prevalence of IHD. H. pylori infected people had a statistically significant, though minor, elevated risk of IHD compared to those without the infection, according to meta-analyses of cross-sectional studies.[29] However, cross-sectional studies cannot establish causality, as they assess exposure and outcome at the same time point. The observed associations may be due to reverse causation or confounding factors not adequately controlled for.

5.2 Case-Control Studies:

Results from case-control studies comparing those with IHD to those without the disease have also been contradictory. A higher prevalence of H. pylori infection in IHD cases relative to controls has been found in certain case-control studies, [30] lending credence to the possibility of a relationship. On the other hand, several case-control studies have not shown a notable variation in the prevalence of H. pylori between the two groups. [31] The observed relationships in case-control studies could be skewed due to selection bias or recollection bias.

5.3 Prospective Cohort Studies:

Prospective cohort studies, which follow initially healthy individuals over time to assess the incidence of IHD based on baseline H. pylori status, provide stronger evidence regarding causality. Several prospective cohort studies have been conducted to examine this association. Prospective studies have shown that those with baseline H. pylori infection are more likely to experience incident IHD events (such as myocardial infarction, stroke, or cardiovascular death) than those without the infection, but this is not always the case. [32] After controlling for conventional cardiovascular risk variables, however, no substantial independent connection was detected in other large-scale prospective cohorts. [33]

5.4 Meta-Analyses and Systematic Reviews:

The growing body of epidemiological evidence has been the subject of multiple systematic reviews and meta-analyses. Meta-analyses of observational studies have shown a lot of variation among research, although they often demonstrate a statistically significant overall connection between H. pylori and IHD. This heterogeneity may be due to differences in study design, population characteristics, geographic location, methods of H. pylori diagnosis, and control for confounding factors. Some meta-analyses have suggested that the association may be stronger in certain subgroups, such as younger individuals or those with specific cardiovascular risk profiles. [34]

5.5 Geographic and Population Variations:

H. pylori infection and IHD prevalence differ by region and demographic. Some regions with high H. pylori prevalence also have high IHD rates, lending credence to a potential link. However, this ecological correlation does not prove causality. Furthermore, socioeconomic factors, dietary habits, and genetic backgrounds, which can vary geographically, may confound the association. Studies conducted in different populations may yield different results due to these contextual variations.

5.6 Impact of H. pylori Eradication:

There has been a dearth of interventional research on the impact of H. pylori removal on cardiovascular outcomes. Eliminating Helicobacter pylori may improve endothelial function or decrease inflammatory markers, according to a few small-scale investigations. [35]

Nevertheless, there is a dearth of large-scale, long-term randomized controlled trials that evaluate the effect of H. pylori eradication on incident IHD events. To evaluate the possible therapeutic value of H. pylori eradication for cardiovascular protection and to give stronger evidence for a causal relationship, such trials are essential.

6. Clinical Implications and Future Directions

Despite the ongoing debate and inconsistent findings, the hypothesis that H. pylori infection may contribute to IHD pathogenesis warrants further investigation. If a causal link is definitively established, it could have significant clinical and public health implications.

6.1 Potential Clinical Relevance:

* Risk Stratification: H. pylori infection status might potentially be considered as an additional risk marker, particularly in individuals at intermediate or low traditional cardiovascular risk. However, current evidence is insufficient to recommend routine H. pylori screening for cardiovascular risk assessment.

* Targeted Eradication: If future research demonstrates a clear benefit of H. pylori eradication for cardiovascular outcomes in specific high-risk groups, targeted eradication strategies could be considered as an adjunct to conventional cardiovascular prevention measures. However, widespread, population-based H. pylori eradication solely for cardiovascular prevention is not currently justified and requires careful consideration of potential antibiotic resistance and ecological consequences.

* Therapeutic Targets: Understanding the specific mechanisms by which H. pylori might influence cardiovascular disease could open avenues for novel therapeutic interventions targeting these pathways. For instance, strategies to mitigate H. pylori-induced systemic inflammation or platelet activation could be explored.

6.2 Research Gaps and Future Directions:

Significant research gaps remain in our understanding of the H. pylori-IHD relationship:

* Causality vs. Association: Future research needs to focus on establishing causality beyond observational associations. Large-scale randomized controlled trials of H. pylori eradication with cardiovascular endpoints are essential.

* Mechanism Elucidation: Further mechanistic studies are needed to delineate the precise biological pathways through which H. pylori might influence atherosclerosis and IHD. This includes in vivo and in vitro studies exploring systemic inflammation, molecular mimicry, platelet activation, and endothelial dysfunction.

* Subgroup Analyses: Future studies should explore whether the association between H. pylori and IHD varies in different subgroups based on age, sex, ethnicity, geographic location, H. pylori virulence factors (e.g., CagA status), or cardiovascular risk profiles.

* Longitudinal Studies with Repeated Measures: Prospective studies with repeated measures of H. pylori status and cardiovascular risk factors over time would provide valuable insights into the temporal relationship and potential causal pathways.

* Integrating Multi-omics Methods: To better understand the intricate relationship between H. pylori, host variables, and cardiovascular disease, epidemiological studies should be conducted alongside multi-omics methods (genomics, proteomics, metabolomics).

Conclusion

Research on the possible connection between Helicobacter pylori infection and Ischemic Heart Disease is an exciting active field. While biological plausibility exists, supported by proposed mechanisms such as systemic inflammation, molecular mimicry, and platelet activation, the epidemiological evidence remains inconclusive and debated. Meta-analyses of observational studies often show a statistically significant association, but significant heterogeneity and the inherent limitations of observational studies preclude definitive conclusions about causality. The effectiveness of H. pylori eradication in lowering cardiovascular risk can only be determined by large-scale interventional trials.

Similar to more conventional risk factors, such as hypertension and hyperlipidemia, there is currently not enough evidence to classify H. pylori infection as a well-established independent risk factor for IHD. However, the possibility of a contributory role, particularly in certain subgroups or through specific mechanisms, cannot be dismissed. Future research, particularly well-designed prospective studies and interventional trials, is crucial to clarify

the complex relationship between H. pylori and IHD.

Until stronger evidence emerges, management of IHD should continue to focus on established cardiovascular risk factors and evidence-based guidelines, while the potential role of H. pylori remains an area of active investigation. A holistic approach to cardiovascular health, encompassing both traditional and emerging risk factors, is essential for effective prevention and treatment of IHD.

References

1. **Hooi, J. K. Y., Lai, W. Y., Ng, W. K., et al.** Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. Gastroenterology**.2017** ; 153(2), 420-429.

2. **Cover, T. L., & Blaser, M. J.** Helicobacter pylori in Health and Disease. Gastroenterology**.2009** ; 136(6), 1863-1873.

3. **Kusters, J. G., van Vliet, A. H. M., & Kuipers, E. J.** Pathogenesis of Helicobacter pylori Infection. Clinical Microbiology Reviews**. 2006** ;19(3), 449-490.

4. **Libby, P., Theroux, P.** Pathophysiology of Coronary Artery Disease. Circulation**.2005;** 111(25), 3481-3488.

5. **World Health Organization.** Cardiovascular diseases (CVDs). **2005**

6. **Yusuf, S., Hawken, S., Ounpuu, S., et al.** Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. The Lancet.**2004** ;364(9438), 937-952.

7. **Epstein, S. E., Zhou, Y. F., Zhu, J.** Infection and Atherosclerosis: Emerging Mechanistic Paradigms. Circulation.**1999** ; 100(5), e20-e25.

8. **Testerman, T. L., & Morris, J.** Beyond the Stomach: Extra-Gastric Helicobacter pylori — A Review. World Journal of Gastroenterology.**2014** ; 20(36), 12781-12793.

9. **Mobley, H. L. T.** Urease for Helicobacter pylori Pathogenesis. Gastroenterology Clinics of North America.**1996** ; 29(3), 717-730.

10. **Kountouras, J., Zavos, K., Polyzos, S. A., et al.** Systemic Inflammation in Helicobacter pylori Infection: A Review. Journal of Gastrointestinal and Liver Diseases.**2017** ; 26(2), 183-189.

11. **IARC Working Group on the Evaluation of Carcinogenic Risks to Humans.** Schistosomes, Liver Flukes and Helicobacter pylori. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol. 61. Lyon: International Agency for Research on Cancer (IARC). **1994**

12. **Malfertheiner, P., Megraud, F., O'Morain, C. A., et al.** Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus Report. Gut.**2017** ; 66(1), 6-30.

13. **Ross, R.** Atherosclerosis--An Inflammatory Disease. New England Journal of Medicine.**1999** ; 340(2), 115-126.

14. **Fuster, V., Badimon, J. J., Badimon, L., & Chesebro, J. H.** The Pathogenesis of Coronary Artery Disease and the Acute Coronary Syndromes. New England Journal of Medicine.**1990** ; 326(4), 242-250.

15. **Libby, P., Ridker, P. M., & Hansson, G. K.** Progress and Challenges in Translating the Biology of Atherosclerosis. Nature.**2011;** 473(7347), 317-325.

16. **Hansson, G. K.** Inflammation, Atherosclerosis, and Coronary Artery Disease. New England Journal of Medicine.**2005** ; 352(16), 1685-1695.

17. **Packard, C. J., & Libby, P.** Inflammation in Atherosclerosis: From Vascular Biology to Biomarker Discovery and Clinical Practice. Clinical Chemistry.**2008** ; 54(1), 24-38.

18. **Muhlestein, J. B., Anderson, J. L., Hammond, E. H., et al.** Infection with Chlamydia pneumoniae Accelerates the Development of Diet-Induced Atherosclerosis in the Rabbit. Circulation.**1998** ;97(7), 633-636.

19. **Cracco, L., Vanucci, L., Traversi, G., et al.** Systemic Inflammatory Response Following Helicobacter pylori Infection. World Journal of Gastroenterology.**2015** ; 21(20), 6165-6179.

20. **Libby, P.** Inflammation in Atherosclerosis. Nature.**2002** ; 420(6917), 868-874.

21. **Davies, T. F.** Infection and Autoimmunity: The Paradoxical Paradigm. Journal of Clinical Endocrinology & Metabolism.**2000** ; 85(12), 4403-4407.

22. **Gerhard, M., Lehn, N., Neumayer, P., et al.** Clinical Relevance of the Helicobacter pylori Gene cagA: Association of Antibody to CagA With

Gastric Adenocarcinoma and Peptic Ulcer. Proceedings of the National Academy of Sciences. **1999 ;** 96(22), 12798-12803.

23. **De Re, V., De Zorzi, M., Alberti, L., et al.** Helicobacter pylori Induces Platelet Aggregation and Platelet Tissue Factor Expression. Thrombosis and Haemostasis.**2003 ;** 90(02), 329-336.

24. **Butt, M. S., Saleem, M. A., Shahid, M., & Hussain, S. S.** Association of Helicobacter pylori Infection With Coagulation Parameters in Patients With Ischemic Heart Disease. Pakistan Journal of Medical Sciences.**2014 ;** 30(5), 987-991.

25. **Yang, Y. I., Choi, J., Park, S. Y., et al.** Association Between Helicobacter pylori Infection and Serum Lipid Profiles in a Korean Population. Journal of Gastroenterology and Hepatology. **2014 ;** 29(11), 1938-1944.

26. **Ishikawa, D., Takagi, A., Tsuda, M., et al.** No Significant Association Between Helicobacter pylori Infection and Serum Lipid Profiles in a Japanese Population. Journal of Gastroenterology and Hepatology.**2007 ;** 22(8), 1299-1304.

27. **Libby, P., & Theroux, P.** Pathophysiology of Coronary Artery Disease. Circulation.**2005 ;** 111(25), 3481-3488.

28. **Gurer, U. S., Ural, A. U., Yildiz, A., et al.** Effects of Helicobacter pylori on Endothelial Function in Patients With and Without Coronary Artery Disease. American Journal of Cardiology.**2005 ;** 96(9), 1239-1242.

29. **Muhsen, K., & Jonasson, J. P.** Helicobacter pylori Infection and Cardiovascular Disease: A Systematic Review and Meta-analysis. American Heart Journal.**2011 ;** 161(5), 829-839.

30. **Patel, P., Vecht, J. A., Palmer, K. R.** Clinical Association Between Helicobacter pylori and Coronary Heart Disease. The American Journal of Cardiology.**1995 ;** 75(7), 497-498.

31. **Wald, N. J., Law, M. R., Morris, J. K., et al.** Helicobacter pylori Infection and Mortality From Ischaemic Heart Disease: Negative Results From a Large Prospective Study. British Medical Journal. **1997 ;** 315(7120), 1387-1391.

32. **Kiechl, S., Egger, G., Oberhollenzer, F., et al.** Helicobacter pylori Seropositivity and Ischemic Heart Disease: Prospective Results of the Bruneck Study. Arteriosclerosis, Thrombosis, and Vascular Biology.**1999 ;** 19(5), 1122-1126.

33. **Whincup, P. H., Mendall, M. A., Perry, I. J., et al.** Prospective Relations Between Helicobacter pylori Infection, Coronary Heart Disease, and Stroke in Middle Aged Men. Heart.**1996 ;** 75(6), 568-572.

34. **Danesh, J., Peto, R.** Risk Factors for Coronary Heart Disease and Stroke: 2. Risk Factors and the Extent to Which They Explain Interindividual Differences in Coronary Heart Disease and Stroke Rates. Journal of the American College of Cardiology.**1998 ;** 32(6), 1627-1636.

35. **Kalay, N., Yildiz, A., Omaygenc, D., et al.** Helicobacter pylori Eradication Improves Endothelial Function in Patients With Coronary Artery Disease. Journal of the American College of Cardiology.**2006 ;** 47(12), 2315-2319.